🇺🇸 metformin and rosiglitazone in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 11

Most-reported reactions

1. Anaphylactic Reaction — 2 reports (18.18%)
2. Abasia — 1 report (9.09%)
3. Balance Disorder — 1 report (9.09%)
4. Chest Pain — 1 report (9.09%)
5. Cough — 1 report (9.09%)
6. Fall — 1 report (9.09%)
7. Pain — 1 report (9.09%)
8. Pancreatitis — 1 report (9.09%)
9. Product Use In Unapproved Indication — 1 report (9.09%)
10. Tendonitis — 1 report (9.09%)

Source database →

Frequently asked questions

Is metformin and rosiglitazone approved in United States?

metformin and rosiglitazone does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for metformin and rosiglitazone in United States?

New York Medical College is the originator. The local marketing authorisation holder may differ — check the official source linked above.